On July 19, American pharmaceutical company MEI Pharma (stock code: MEIP) announced a strategic transformation to establish a dedicated Litecoin treasury strategy. Currently, over $100 million in funding commitments have been made for this project.

As part of the deal, the biotech company will appoint Litecoin founder Charlie Lee to its board of directors. GSR will also receive a board seat and play a significant role in the company's digital asset and fund management advisory committee. Additionally, the Litecoin Foundation has invested in MEI Pharma, as the company's treasury strategy aligns closely with the core mission of the Litecoin Foundation to promote global Litecoin adoption.

Following the announcement, MEIP's stock price surged by 83.37% in pre-market trading on Friday, continuing a previous day's increase of 16.58%, with a peak reaching $9, currently stabilizing at $6.30. The trading volume exceeded 13 million shares that day, far surpassing the average daily volume of 26,000 shares over the past three months. This shift not only reflects the market's positive expectations for the company's blockchain transformation but also marks the official launch of another "altcoin micro-strategy" model following mainstream crypto assets like ETH, SOL, and BNB, ushering in a new chapter of institutional allocation for Litecoin (LTC).

MEI Pharma Completes Strategic Transformation: The First Public Company to Establish a Litecoin Strategic Reserve

MEI Pharma, Inc. is a biopharmaceutical company focused on the research and development of small molecule drug compounds, with core R&D projects including the CDK inhibitor Voruciclib for treating B-cell malignancies and the mitochondrial-targeted anti-cancer drug ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, California, USA.

On July 19, 2025, MEI Pharma announced its alignment with blockchain finance, launching a new round of private equity investment (PIPE) and planning to incorporate Litecoin (LTC) into its corporate asset allocation, becoming the first publicly traded biotech company to use LTC as a primary financial reserve asset.

According to the announcement, this round of financing is co-led by Titan Partners Group and cryptocurrency trading firm GSR, planning to issue 29,239,767 shares of common stock or equivalent pre-paid warrants at a price of $3.42 per share, with a total financing scale of approximately $100 million. The transaction is expected to be completed around July 22, 2025, subject to customary regulatory and closing conditions.

This financing is not just a capital operation but also signifies that MEI is undergoing a deep strategic transformation. The company stated that it had systematically assessed the sustainability of traditional biotech business models and decided to embrace the blockchain and decentralized finance (DeFi) space, planning to restructure its treasury with Litecoin as the core asset and engage in long-term cooperation with the Litecoin Foundation and GSR.

In response to this collaboration, Charlie Lee stated, "Since its founding in 2011, Litecoin has adhered to the principles of being fast, secure, and decentralized. It is gratifying to see publicly traded companies like MEI embrace these principles. This not only reflects the growing confidence of institutions in LTC but also lays the foundation for its further expansion in traditional capital markets."

Why Choose Litecoin

Litecoin is one of the earliest altcoins to enter the market, created by former Google engineer Charlie Lee in 2011. Its core architecture is based on Bitcoin's open-source code, with several optimizations and upgrades made on that foundation. Compared to Bitcoin, Litecoin generates blocks faster, uses the Scrypt proof-of-work (PoW) algorithm, making it more suitable for ordinary hardware mining and lowering the participation threshold. Its total supply is set at 84 million coins, possessing deflationary properties similar to Bitcoin—every 840,000 blocks will trigger a halving mechanism for block rewards.

As a representative of the first generation of altcoins, Litecoin has always been committed to improving on-chain transaction efficiency and scalability, with advantages such as low fees and fast processing speeds. In recent years, Litecoin has gradually expanded its payment use cases, including travel companies, convenience stores, real estate agencies, and online e-commerce. In 2021, the Litecoin Foundation announced a partnership with a financial service provider to issue a Visa debit card, allowing users to convert LTC to USD in real-time for payment, further solidifying its practical value.

Since the establishment of Litecoin in 2011, Charlie Lee has been the core driving force behind this ecosystem. He has not only advocated for technological innovation but has also led several key upgrade processes—including the selective integration of privacy features and the activation of Segregated Witness. Charlie Lee has also invested in promoting the Lightning Network experiment, mining pool collaboration, and developer community building, laying a solid foundation for the long-term development of both the Bitcoin and Litecoin networks.

Now, his deep involvement in MEI Pharma's Litecoin treasury has once again boosted market confidence in the "Litecoin treasury" strategy. As emphasized by the Litecoin Foundation in its announcement, "For 14 years, Litecoin has consistently provided millions of users with a stable, low-cost, and easily accessible network." This collaboration with MEI not only signifies Litecoin's first inclusion in the financial structure of a publicly traded company in the U.S. but also represents a strategically significant institutional-level financial experiment under the direct participation of its founder.

Meanwhile, market expectations for Litecoin among institutions are rapidly heating up. According to data from the decentralized prediction platform Polymarket, as of the end of 2025, the probability of the U.S. Securities and Exchange Commission (SEC) approving a Litecoin spot ETF has reached 86%. This not only reflects investors' optimistic expectations for Litecoin's regulatory prospects but also indicates its gradual entry into the ranks of "mainstream assets" amid the wave of compliance.

Once the spot ETF is approved, Litecoin will join Bitcoin and Ethereum as core targets in traditional financial investment portfolios, providing a legitimate and compliant allocation path for institutional funds. This will enhance LTC's market liquidity and valuation anchoring, while further strengthening its market positioning as a "payment-oriented digital asset," becoming a bridge linking the on-chain world with Wall Street funds.

Conclusion

With MEI Pharma becoming the first publicly traded company to incorporate LTC into its financial reserves, following the "micro-strategy model" initiated by mainstream tokens like Ethereum, BNB, and SOL, Litecoin has officially joined this institutional accumulation camp, signaling the launch of another altcoin "treasury path." On the day of the announcement, Litecoin strongly broke through its downward channel, rising over 6% within 24 hours, with prices reaching as high as $106, and subsequently continuing to rise to $115. This not only marks a reassessment of LTC's asset attributes but also further reinforces the role of the "altcoin micro-strategy" as a driving force in this bull market. Coupled with the ETF concept and accelerated institutional accumulation, the altcoin season is quietly beginning.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。